A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.

Abstract

PURPOSE This trial was conducted to determine the maximum tolerated dose (MTD) and preliminary efficacy of buparlisib, an oral pan-class I PI3K inhibitor, plus fulvestrant in postmenopausal women with metastatic estrogen receptor positive (ER(+)) breast cancer. EXPERIMENTAL DESIGN Phase IA employed a 3+3 design to determine the MTD of buparlisib daily… (More)
DOI: 10.1158/1078-0432.CCR-15-1745

Topics

6 Figures and Tables

Cite this paper

@article{Ma2016API, title={A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.}, author={Cynthia X. Ma and Jingqin Luo and Michael J. Naughton and Foluso O Ademuyiwa and Rama Suresh and Malachi Griffith and Obi L. Griffith and Zachary L. Skidmore and Nicholas C. Spies and Avinash Ramu and Lee Trani and Timothy J. Pluard and Gayathri Nagaraj and Shana Thomas and Zhanfang Guo and Jeremy Hoog and Jing Han and Elaine R. Mardis and Craig Lockhart and Matthew J. Ellis}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2016}, volume={22 7}, pages={1583-91} }